![Eric Nils Gunnar Wahlberg](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Eric Nils Gunnar Wahlberg
Corporate Officer/Principal bij University of Linköping
Profiel
Eric Nils Gunnar Wahlberg is currently a Professor of Vascular Surgery at the University of Linköping.
He previously worked as a Director at ClanoTech AB, a Clinical Team Leader at Novartis AG, and a Vice President of Clinical at AstraZeneca UK Ltd.
Actieve functies van Eric Nils Gunnar Wahlberg
Bedrijven | Functie | Begin |
---|---|---|
University of Linköping
![]() University of Linköping Other Consumer ServicesConsumer Services Linköping University Hospital provides healthcare services. | Corporate Officer/Principal | - |
Eerdere bekende functies van Eric Nils Gunnar Wahlberg
Bedrijven | Functie | Einde |
---|---|---|
AstraZeneca UK Ltd.
![]() AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
NOVARTIS AG | Corporate Officer/Principal | - |
ClanoTech AB
![]() ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
NOVARTIS AG | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
ClanoTech AB
![]() ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Health Technology |
AstraZeneca UK Ltd.
![]() AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom. | Commercial Services |